Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988890314> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2988890314 endingPage "394" @default.
- W2988890314 startingPage "389" @default.
- W2988890314 abstract "Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibitors of programmed death-1 and programmed death-ligand 1. Preclinical studies have shown that ICIPs have shown good clinical efficacy and durable response in diverse cancers. Among them, atezolizumab (MPDL3280), an anti-PD-L1 monoclonal antibody, is being investigated as a potential therapy against solid tumors and hematologic malignancies in humans. Pseudoprogression is reported as one of the unique phenomena with immune therapeutic agents. Here we report case of a person with advanced NSCLC who developed pseudoprogression after receiving immunotherapy. We hope this case could help clinicians to make appropriate decision when assessing therapeutic effects of immunotherapy. .【中文题目：肺腺癌患者在Atezolizumab治疗过程中出现假性进展的案例报道】 【中文摘要：肺癌是全球癌症相关死亡的最常见原因。根据病理类型的不同，肺癌可分为非小细胞肺癌（non-small cell lung cancer, NSCLC）和小细胞肺癌（small cell lung cancer, SCLC）。其中NSCLC约占所有肺癌患者的85%。免疫检查点抑制剂（immune checkpoint inhibitors, ICIPs）是一类针对程序性死亡受体-1（programmed cell death protein 1, PD-1）及其配体（programmed death-ligand 1, PD-L1）的抑制剂，已有研究结果显示ICIPs在许多不同的癌症中具有良好且持久的抗癌疗效，其中抗PD-L1单克隆抗体Atezolizumab（MPDL3280）正在实体瘤和恶性血液病中开展临床研究。据报道，假性进展是免疫治疗中可能出现的独特现象之一。本文中我们报道了1例晚期NSCLC接受免疫治疗后发生假性进展的病例，希望这一案例可以更好地帮助临床医生恰当评估免疫治疗的疗效，并作出最恰当的治疗决策。】 【中文关键词：肺肿瘤；免疫治疗；PD-L1；Atezolizumab；假性进展】." @default.
- W2988890314 created "2019-11-22" @default.
- W2988890314 creator A5065172118 @default.
- W2988890314 creator A5076476567 @default.
- W2988890314 creator A5077357809 @default.
- W2988890314 date "2019-06-20" @default.
- W2988890314 modified "2023-09-27" @default.
- W2988890314 title "[A Case of Pseudoprogression During Atezolizumab Therapy in Lung Adenocarcinoma]." @default.
- W2988890314 cites W2095267413 @default.
- W2988890314 cites W2100158834 @default.
- W2988890314 cites W2101571970 @default.
- W2988890314 cites W2117692326 @default.
- W2988890314 cites W2197694832 @default.
- W2988890314 cites W2560367415 @default.
- W2988890314 cites W2586493371 @default.
- W2988890314 cites W2592144107 @default.
- W2988890314 cites W2625725779 @default.
- W2988890314 cites W2750530006 @default.
- W2988890314 cites W2803803995 @default.
- W2988890314 cites W2821553560 @default.
- W2988890314 cites W2886287242 @default.
- W2988890314 cites W2888955278 @default.
- W2988890314 cites W2890530544 @default.
- W2988890314 cites W2894854986 @default.
- W2988890314 doi "https://doi.org/10.3779/j.issn.1009-3419.2019.06.10" @default.
- W2988890314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6580083" @default.
- W2988890314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31196374" @default.
- W2988890314 hasPublicationYear "2019" @default.
- W2988890314 type Work @default.
- W2988890314 sameAs 2988890314 @default.
- W2988890314 citedByCount "0" @default.
- W2988890314 crossrefType "journal-article" @default.
- W2988890314 hasAuthorship W2988890314A5065172118 @default.
- W2988890314 hasAuthorship W2988890314A5076476567 @default.
- W2988890314 hasAuthorship W2988890314A5077357809 @default.
- W2988890314 hasConcept C121608353 @default.
- W2988890314 hasConcept C126322002 @default.
- W2988890314 hasConcept C143998085 @default.
- W2988890314 hasConcept C2775949291 @default.
- W2988890314 hasConcept C2776256026 @default.
- W2988890314 hasConcept C2777701055 @default.
- W2988890314 hasConcept C2780030458 @default.
- W2988890314 hasConcept C2781182431 @default.
- W2988890314 hasConcept C502942594 @default.
- W2988890314 hasConcept C71924100 @default.
- W2988890314 hasConceptScore W2988890314C121608353 @default.
- W2988890314 hasConceptScore W2988890314C126322002 @default.
- W2988890314 hasConceptScore W2988890314C143998085 @default.
- W2988890314 hasConceptScore W2988890314C2775949291 @default.
- W2988890314 hasConceptScore W2988890314C2776256026 @default.
- W2988890314 hasConceptScore W2988890314C2777701055 @default.
- W2988890314 hasConceptScore W2988890314C2780030458 @default.
- W2988890314 hasConceptScore W2988890314C2781182431 @default.
- W2988890314 hasConceptScore W2988890314C502942594 @default.
- W2988890314 hasConceptScore W2988890314C71924100 @default.
- W2988890314 hasIssue "6" @default.
- W2988890314 hasLocation W29888903141 @default.
- W2988890314 hasLocation W29888903142 @default.
- W2988890314 hasOpenAccess W2988890314 @default.
- W2988890314 hasPrimaryLocation W29888903141 @default.
- W2988890314 hasRelatedWork W2378830451 @default.
- W2988890314 hasRelatedWork W2414633226 @default.
- W2988890314 hasRelatedWork W2908922480 @default.
- W2988890314 hasRelatedWork W2988890314 @default.
- W2988890314 hasRelatedWork W3023819640 @default.
- W2988890314 hasRelatedWork W3031134649 @default.
- W2988890314 hasRelatedWork W3106063606 @default.
- W2988890314 hasRelatedWork W3171615116 @default.
- W2988890314 hasRelatedWork W3206932502 @default.
- W2988890314 hasRelatedWork W3215044659 @default.
- W2988890314 hasVolume "22" @default.
- W2988890314 isParatext "false" @default.
- W2988890314 isRetracted "false" @default.
- W2988890314 magId "2988890314" @default.
- W2988890314 workType "article" @default.